International Business News - NVS http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Shares of drug maker King Pharmaceuticals Inc. rose Thursday after a Natixis Bleichroeder analyst upgraded the stock, pointing to its "astounding" low levels. http://www.ibtimes.com/articles/20081009/king-rises-after-analyst-upgrades-on-lower-risk.htm Thu, 09 Oct 2008 15:43:31 EDT A look at what happened in some stock markets around the world Thursday: ___ http://www.ibtimes.com/articles/20081009/a-look-at-financial-developments-around-the-world.htm Thu, 09 Oct 2008 19:41:52 EDT Switzerland's blue-chip index SMI dropped 4.5 percent Thursday to close below 6,000 for the first time since April 2005. Declines in shares of Swiss pharmaceutical companies helped pull down the Swiss Market Index to 5,798.84 points down 36.54 percent from the year's high of 9243.79 points on Oct. 11, 2007. http://www.ibtimes.com/articles/20081009/swiss-index-closes-below-6-000.htm Thu, 09 Oct 2008 14:11:57 EDT Cowen and Co. analyst Sara Michelmore downgraded shares of Gen-Probe Inc. to "Neutral" from "Outperform" Friday, saying sales of the blood-screening system Ultrio not reaching previous expectations. http://www.ibtimes.com/articles/20081003/ahead-of-the-bell-gen-probe-downgraded.htm Fri, 03 Oct 2008 08:13:38 EDT Biotechnology company Molecular Insight Pharmaceuticals Inc. on Monday added four new directors to its board, including employees of GlaxoSmithKline PLC and Novartis AG. http://www.ibtimes.com/articles/20080922/molecular-insight-names-4-directors-to-board.htm Mon, 22 Sep 2008 11:06:46 EDT Biotechnology company Amgen Inc. released widely anticipated data Tuesday showing its osteoporosis drug candidate denosumab dramatically cut the risk of spinal and hip fractures in postmenopausal women, compared with placebo. http://www.ibtimes.com/articles/20080916/amgens-denosumab-lowers-fracture-risk-in-study.htm Tue, 16 Sep 2008 17:32:44 EDT Swiss pharmaceutical company Novartis AG said Friday it would take a $235 million impairment charge in the next quarter after deciding to drop its development of a new antibiotic drug. http://www.ibtimes.com/articles/20080829/novartis-plans-235m-charge-after-dropping-drug.htm Fri, 29 Aug 2008 12:17:08 EDT Among the stock activity stories for Wednesday, Aug. 27, from AP Financial News: NEW YORK (AP)--Shares of drug developer NexMed Inc. plunged Wednesday after the company said its development partner, Swiss pharmaceutical company Novartis AG, will not ask for regulatory approval of a developing nail fungus treatment. http://www.ibtimes.com/articles/20080827/movers-roundup-nexmed-bristol-myers-squibb.htm Wed, 27 Aug 2008 14:31:25 EDT Shares of drug developer NexMed Inc. plunged Wednesday after the company said its development partner, Swiss pharmaceutical company Novartis AG, will not ask for regulatory approval of a developing nail fungus treatment. http://www.ibtimes.com/articles/20080827/nexmed-shares-plunge-on-move-to-nix-product-filing.htm Wed, 27 Aug 2008 17:14:37 EDT Drug maker Novartis AG said Wednesday that the Food and Drug Administration has granted a priority review to its drug Gleevec as a treatment for intestinal cancer--meaning the agency intends to make a ruling within six months. http://www.ibtimes.com/articles/20080827/novartis-says-fda-gives-gleevec-priority-review.htm Wed, 27 Aug 2008 07:54:07 EDT Novartis AG said Wednesday that its blindness drug Lucentis has won funding approval in England and Wales, making it freely available to tens of thousands of patients. http://www.ibtimes.com/articles/20080827/novartis-drug-receives-funding-approval.htm Wed, 27 Aug 2008 12:40:15 EDT Drug developer NexMed Inc. said Tuesday that its development partner, Swiss drug maker Novartis AG, has decided not to submit a new drug application for an experimental nail fungus treatment to the Food and Drug Administration at this time. http://www.ibtimes.com/articles/20080826/nexmed-shares-sink-on-novartis-decision.htm Tue, 26 Aug 2008 17:23:47 EDT Flu vaccine makers have begun shipping their products already, earlier than usual, and for the first time every strain included in the vaccine is new. http://www.ibtimes.com/articles/20080814/flu-vaccine-makers-ship-more-doses-earlier.htm Thu, 14 Aug 2008 14:53:12 EDT Swiss pharmaceutical maker Novartis AG spent over $1.3 million lobbying the U.S. government in the second quarter on drug and health care issues, according to a recent disclosure form. http://www.ibtimes.com/articles/20080811/novartis-lobbying-totaled-1-3-million-in-2q.htm Mon, 11 Aug 2008 14:53:00 EDT Biotechnology company Alnylam Pharmaceuticals Inc. said Thursday its second-quarter loss increased slightly, as rising expenses canceled out improved revenue from collaborations. http://www.ibtimes.com/articles/20080807/alnylam-2q-loss-edges-higher-on-research-costs.htm Thu, 07 Aug 2008 07:19:34 EDT Nestle SA, the worlds biggest food and drink company, reported 6.1 percent growth in first-half net profit Thursday despite rising transport and raw materials costs and slowing bottled water sales amid criticism from environmentalists. http://www.ibtimes.com/articles/20080807/nestles-1h-profits-up-6-1-percent.htm Thu, 07 Aug 2008 12:39:45 EDT Novartis AG said Monday the Food and Drug Administration approved the drugs Diovan HCT and Exforge as initial treatments for high blood pressure. The drugs were already approved as secondary treatments. They are both once-daily tablets. http://www.ibtimes.com/articles/20080804/novartis-gets-expanded-blood-pressure-drug-ok.htm Mon, 04 Aug 2008 09:08:24 EDT An Alabama judge has scheduled a trial for October in the state's drug pricing lawsuit against drug manufacturer Bristol-Myers Squibb Co. Montgomery County Circuit Judge Charles Price on Wednesday said jury selection will begin Oct. 27. Bristol-Myers Squibb is one of more than 70 companies the state has sued for allegedly overcharging the state's Medicaid program. http://www.ibtimes.com/articles/20080723/date-set-for-next-trial-of-alabamas-drug-lawsuits.htm Wed, 23 Jul 2008 15:19:16 EDT Canada's national public health department on Friday warned consumers not to use a certain type of generic prescription eye drop made by Novartis AG's Sandoz unit because of a heightened safety risk. http://www.ibtimes.com/articles/20080718/novartis-unit-recalling-prescription-eye-drops.htm Fri, 18 Jul 2008 17:27:39 EDT Shares of Barr Pharmaceuticals Inc. soared Thursday on reports of buyout talks between Barr and industry leader Teva Pharmaceutical Industries Ltd. The speculation also lifted shares of other generic drug makers. http://www.ibtimes.com/articles/20080717/sector-snap-teva-barr-talk-lifts-generics-makers.htm Thu, 17 Jul 2008 15:17:07 EDT